Bortezomib

NDC 68001-534 · BluePoint Laboratories

Generic nameBortezomib

Dosage formINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

RouteINTRAVENOUS, SUBCUTANEOUS

Active ingredient(s)BORTEZOMIB

Strength3.5 mg/1

Pharmacologic classProteasome Inhibitor [EPC], Proteasome Inhibitors [MoA]

Marketing categoryANDA

Packages

68001-534-36 — 1 VIAL in 1 CARTON (68001-534-36) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL

J9041 — Injection, bortezomib, 0.1 mg Medicare Part B payment limit (ASP + 6%): $2.04

FDA lists these products with the same active ingredient.

25021-262 — BORTEZOMIB, 31722-303 — Bortezomib, 43598-426 — Bortezomib, 51817-586 — bortezomib, 55150-337 — BORTEZOMIB, 60505-6050 — bortezomib, 63020-049 — bortezomib, 63323-821 — Bortezomib, 63759-3032 — Bortezomib, 67184-0530 — Bortezomib, 68001-540 — Bortezomib, 68001-541 — Bortezomib, 68083-650 — Bortezomib, 68083-651 — Bortezomib, 70069-836 — bortezomib, 70121-2484 — Bortezomib, 70511-161 — bortezomib, 70511-162 — bortezomib, 70710-1411 — BORTEZOMIB, 70771-1708 — BORTEZOMIB, +11 more

From the FDA National Drug Code Directory, retrieved 2026-08-24. Product listings are submitted by labelers; FDA does not verify them.